Nature Reviews Clinical Oncology

ISSN: 1759-4774

Journal Home

Journal Guideline

Nature Reviews Clinical Oncology Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Clinical Oncology is a journal indexed in SJR in Oncology with an H index of 155. It has an SJR impact factor of 12,214 and it has a best quartile of Q1.

Nature Reviews Clinical Oncology focuses its scope in these topics and keywords: biomarkerdriven, discovery, trials, cancer, standard, clinical, biopsy, drug, hcc, gvhddacomitinib, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

WOS Scopus
Categories: Oncology (Q1)
Price

- €

Gold OA

-

Green OA

- €

Non OA

Metrics

Nature Reviews Clinical Oncology

12,214

SJR Impact factor

155

H Index

144

Total Docs (Last Year)

587

Total Docs (3 years)

7574

Total Refs

8185

Total Cites (3 years)

277

Citable Docs (3 years)

13,76

Cites/Doc (2 years)

52,60

Ref/Doc

Aims and Scope


biomarkerdriven, discovery, trials, cancer, standard, clinical, biopsy, drug, hcc, gvhddacomitinib, glioblastomanivolumab, learntearly, limit, liquid, lorlatinibfrom, lymphomahas, lymphomaliquid, gameavoiding, fits, era, biopsies, bloodtruly, breast, cancergenetics, chemoradiation, chemosensitivityrectal, combination, dlbcl, effective, elderly, end,


Best articles

A case of variant angina in a patient under chronic treatment with sorafenib

View more

A promising vaccine for glioblastoma multiforme

View more

Abiraterone treatment improves overall survival in patients with mCRPC

View more

ADAM8 provides new hope in pancreatic cancer

View more

Advanced Hodgkin lymphoma - balancing toxicity and cure

View more

ALL: reducing cardiomyopathy

View more

ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?

View more

Biomarker potential of CA-125 enhanced

View more

Bortezomib and dexamethasone induction for multiple myeloma

View more

BRAF and MEK inhibitors - good news comes in twos!

View more

Can less really be more in melanoma?

View more

Celebrating 10 years since launch

View more
SHOW MORE ARTICLES

Cetuximab's tip to become irresistible

View more

Cisplatin more effective when given less often

View more

CONKO conquers

View more

Conscripts of the infinite armada: systemic cancer therapy using nanomaterials

View more

CRISPR-Cas: a tool for cancer research and therapeutics

View more

CSF DNA provides a snapshot of the glioma genome

View more

CTCs - a predictive approach for targeted cancer therapy

View more

Dacomitinib: getting on target after negative ARCHER trial

View more

Does nodal micrometastasis impact outcome in biliary cancer?

View more

Driver genes are mutated early in the course of oesophageal adenocarcinoma

View more

Erratum: Clinical trials of human papillomavirus vaccines and beyond

View more

Erratum: Managing bone metastases and reducing skeletal related events in prostate cancer

View more

Comments

No comments ... Be the first to comment!